nach oben

Erschienen in:

01.07.2021 | News item

Interstitial lung disease or pneumonitis with CDK 4/6 inhibitors

Erschienen in: Reactions Weekly | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Excerpt

In the UK, there have been reports of interstitial lung disease or pneumonitis in patients treated with cyclin-dependent kinase 4 and 6 (CDK 4/6) inhibitors. …

Medicines and Healthcare products Regulatory Agency. CDK4/6 inhibitors (abemaciclib, palbociclib, ribociclib): reports of interstitial lung disease and pneumonitis, including severe cases. Drug Safety Update 14: No. 11, 17 Jun 2021. Available from: URL: https://www.gov.uk/drug-safety-update/cdk4-slash-6-inhibitors-abemaciclibv-palbociclibv-ribociclibv-reports-of-interstitial-lung-disease-and-pneumonitis-including-severe-cases

Titel: Interstitial lung disease or pneumonitis with CDK 4/6 inhibitors
Publikationsdatum: 01.07.2021
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2021
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-021-98121-x

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2021

Multiple drugs

Oxcarbazepine

Mycophenolate-mofetil/prednisone/tacrolimus

Mycophenolate-mofetil

Clozapine/sodium-valproate interaction

Fentanyl